Hormoner-forskning
GH-sekretagoger, rekombinant GH og gonadotropiner. Nedenfor er den publicerede litteratur for hver forbindelse inden for dette område — 225 studier i alt, 84 af dem publiceret siden 2023, alle linket til deres kildepost.
- HormonerTidlig klinisk
CJC-1295
CJC-1295 refererer til to relaterede growth hormone-releasing hormone (GHRH)-receptoragonister afledt af det N-terminale 29-aminosyrefragment af humant GHRH. DAC-formen bærer en maleimidopropionyl-linker, der danner et kovalent drug affinity complex med cirkulerende albumin, hvilket forlænger plasmahalveringstiden til cirka en til to uger og producerer en vedvarende forhøjelse af GH og IGF-1; non-DAC-formen, mere korrekt betegnet modified GRF(1-29), mangler linkeren og bibeholder kun de tetrasubstituerede backbone-modifikationer, der modstår dipeptidyl peptidase-IV-spaltning, hvilket giver en kort virkningsvarighed sammenlignelig med sermorelin. Humane data er begrænset til et lille antal fase I- og fase II-studier af DAC-formen udført i 2005-2009, som fastslog en dosisafhængig, forlænget forhøjelse af GH og IGF-1 med bevaret GH-pulsatilitet. Der blev ikke identificeret noget peer-reviewed randomiseret kontrolleret studie af non-DAC modified GRF(1-29)-formen, og størstedelen af litteraturen udgivet siden 2019 vedrører anti-doping detektionsmetodik eller narrative reviews af uautoriseret peptidbrug snarere end nye kliniske data.
- Studier
- 16
- Siden 2023
- 8
- Nyeste
- 2026
- HormonerTidlig klinisk
CJC-1295 + Ipamorelin
Ingen peer-reviewed klinisk forsøg, der administrerede CJC-1295 sammen med ipamorelin, blev identificeret; en PubMed-søgning, der krydsede begge peptidnavne, returnerede kun narrative reviews, dopingkontrol-analytiske metoder og produktkvalitetsanalyser, uden noget interventionelt studie af parret. Den tilgængelige evidens er derfor på komponentniveau og omfatter randomiserede humane studier af CJC-1295 (en langtvirkende GHRH-analog) og af ipamorelin (en selektiv GHS-R1a-agonist) evalueret separat, sammen med en ældre samling humant arbejde om co-administration af GHRH med growth hormone-releasing peptider eller ghrelin, som etablerede, at de to receptorveje interagerer mere end additivt. Nyere 2024-2026-litteratur behandlede denne kombination næsten udelukkende som et ikke-godkendt, compounded produkt anvendt uden for reguleret medicin og karakteriserede dets kliniske evidensgrundlag som fraværende snarere end negativt.
- Studier
- 15
- Siden 2023
- 5
- Nyeste
- 2026
- HormonerGodkendt lægemiddel
HCG
Human chorionic gonadotropin is a heterodimeric placental glycoprotein hormone that shares an alpha subunit with LH, FSH and TSH and signals through the luteinizing hormone/chorionic gonadotropin receptor (LHCGR), reproducing LH activity with a substantially longer circulating half-life. Urinary-derived hCG and recombinant choriogonadotropin alfa are approved agents used to trigger final oocyte maturation and ovulation in assisted reproduction, to support Leydig-cell testosterone production and induce or maintain spermatogenesis in male hypogonadotropic hypogonadism, and historically as hormonal therapy for undescended testis. Serum hCG measurement is also a core diagnostic assay in pregnancy monitoring and in gestational trophoblastic disease. The evidence base is large and dominated by randomised trials and their syntheses, so recent systematic reviews, network meta-analyses and Cochrane reviews carry most of the weight; controlled evidence does not support hCG as a weight-loss agent.
- Studier
- 40
- Siden 2023
- 15
- Nyeste
- 2026
- HormonerGodkendt lægemiddel
HMG
Human menopausal gonadotropin (menotropins) is a urinary-derived gonadotropin preparation containing both follicle-stimulating hormone and luteinizing hormone activity, the latter contributed substantially by chorionic gonadotropin retained during purification. Highly purified formulations (hp-hMG) have been evaluated against recombinant FSH and against rFSH plus recombinant LH in a large randomised-controlled-trial literature covering ovarian stimulation for IVF/ICSI, ovulation induction, and combined gonadotropin therapy for spermatogenesis induction in male hypogonadotropic hypogonadism. A 2026 Cochrane update reported probable advantages for hMG/hp-hMG over rFSH in live birth and ovarian hyperstimulation syndrome, while other recent systematic reviews found comparable live birth with differing oocyte yields, and the field remains characterised by heterogeneity in dosing, protocol and endpoint definition.
- Studier
- 37
- Siden 2023
- 16
- Nyeste
- 2026
- HormonerKun præklinisk
IGF-1 LR3
Long R3 IGF-I (LR3-IGF-I) is a recombinant analogue of human IGF-I with a 13-amino-acid N-terminal extension and arginine in place of glutamate at position 3, developed in Adelaide in the early 1990s. These changes sharply reduced binding to IGF-binding proteins, and in cell and rodent studies the analogue was several-fold more potent than native IGF-I for anabolic and gut-growth effects despite being cleared from plasma more rapidly. In pigs and marmosets it produced stronger and longer-lasting hypoglycaemia than IGF-I, it suppressed growth hormone in pigs and monkeys, and it reduced growth in pigs. Recent animal studies reported no cognitive benefit in an Alzheimer's mouse model and no growth benefit in growth-restricted fetal sheep. No human studies have been published, and anti-doping laboratories have identified research-grade and degraded forms in black-market products.
- Studier
- 15
- Siden 2023
- 4
- Nyeste
- 2026
- HormonerTidlig klinisk
Ipamorelin
Ipamorelin is a synthetic pentapeptide growth hormone secretagogue that acts as a selective agonist at the growth hormone secretagogue receptor 1a (GHS-R1a, the ghrelin receptor). It was first characterised in 1998 as the first secretagogue in its class to release growth hormone with potency comparable to GHRP-6 while not significantly elevating ACTH or cortisol above levels seen after GHRH stimulation. Preclinical work has examined longitudinal bone growth, bone mineral content, gastrointestinal motility, nociception and cisplatin-induced weight loss, and human pharmacokinetic-pharmacodynamic modelling has been published. Clinical development advanced to a randomised placebo-controlled phase 2 trial in postoperative ileus after bowel resection, which did not meet its primary endpoint; recent literature consists largely of narrative reviews on unapproved performance-enhancing and therapeutic peptides.
- Studier
- 18
- Siden 2023
- 9
- Nyeste
- 2026
- HormonerTidlig klinisk
Kisspeptin-10
Kisspeptin-10 (KP-10) is the C-terminal decapeptide fragment of the KISS1 gene product and an agonist at the kisspeptin receptor KISS1R (GPR54). Loss-of-function mutations in KISS1R were shown in 2003 to cause normosmic hypogonadotropic hypogonadism, establishing kisspeptin signalling as an upstream regulator of gonadotropin-releasing hormone secretion. Human administration studies, largely conducted at Imperial College London, have examined intravenous, subcutaneous and intranasal kisspeptin and its longer isoform kisspeptin-54 in healthy volunteers and in reproductive disorders. Kisspeptin is an investigational agent; no kisspeptin peptide is approved as a medicine in any major jurisdiction.
- Studier
- 42
- Siden 2023
- 14
- Nyeste
- 2026
- HormonerGodkendt lægemiddel
Somatropin
Somatropin is a 191-amino-acid recombinant form of human growth hormone that acts through the growth hormone receptor and the downstream JAK/STAT pathway, largely via hepatic and local induction of insulin-like growth factor 1 (IGF-1). It has been an approved therapeutic since the mid-1980s and carries one of the larger clinical evidence bases in endocrinology, spanning childhood and adult growth hormone deficiency, Turner syndrome, Prader-Willi syndrome, small-for-gestational-age short stature and idiopathic short stature. The contemporary literature is dominated by systematic reviews, network meta-analyses and consensus statements, with a recent centre of gravity on long-acting weekly analogues (somapacitan, somatrogon, lonapegsomatropin, pegylated formulations) benchmarked against daily somatropin. Long-term registry and cohort surveillance has focused on mortality, malignancy incidence and metabolic outcomes.
- Studier
- 42
- Siden 2023
- 13
- Nyeste
- 2026
Senest publiceret forskning
Analysis of growth hormone releasing hormone and its analogs in urine using nano liquid chromatography coupled with quadrupole/orbitrap mass spectrometry
Journal of Pharmaceutical and Biomedical Analysis · CJC-1295 som analyt; human urin, udvikling af analytisk metode
PubMed · 41138283Injectable Peptides in Sports Medicine: A Structured Narrative Review of Evidence, Safety, and Antidoping Implications
JBJS Reviews · CJC-1295 inden for GH-secretagog-klassen; struktureret narrativt review af litteratur fra 2020-2025
PubMed · 42160466Peptide Supplements and Their Therapeutic Applications in Sports Medicine
The American Journal of Sports Medicine · CJC-1295 (form ikke konsekvent skelnet); scoping review af seks peptider
PubMed · 42578445Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance
Sports Medicine · CJC-1295 blandt uautoriserede peptider; narrativt review
PubMed · 41966639The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration
Frontiers in Endocrinology · CJC-1295 med og uden DAC; narrativt review af GH-IGF1-akse-peptider
PubMed · 42395176Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives
International Journal of Molecular Sciences · CJC-1295 blandt endokrint aktive peptider; litteraturreview af 106 artikler
PubMed · 42123471Injectable Peptides in Sports Medicine: A Structured Narrative Review of Evidence, Safety, and Antidoping Implications.
JBJS Rev · Struktureret narrativ review af injicerbare peptider
PubMed · 42160466Real-world diagnostic performance of the macimorelin stimulation test in the diagnosis of adult growth hormone deficiency.
Pituitary · Real-world klinisk kohorte, der undergår GH-stimuleringstest
PubMed · 41793495
Kun til forskningsformål. Ikke til humant forbrug, diagnose, behandling eller forebyggelse af nogen tilstand. Intet på denne side er medicinsk rådgivning.